In addition, disruption of the IL6-STAT3 signaling pathway can overcome resistance to PI3K inhibitors, suggesting that combined blockade of STAT3 and PI3K signaling might be a more efficient therapeutic strategy for breast cancer (Yang et al., 2014). The gene discussed is IL6; the disease is breast carcinoma.